)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CelLBxHealth
CelLBxHealth (CLBX) investor relations material
CelLBxHealth Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary21 Oct, 2026
Executive summary
Q3 new business rose threefold YoY to £0.3m; 9M cash operating loss fell 60% to £4.0m, while FY 2026 revenue guidance was revised to ~£1.8m due to timing effects from operational realignment.
FY 2027 revenue is expected to reach £3.0m–£4.0m, supported by stronger commercial momentum, an expanding pipeline and operational improvements.
Financial highlights
Q3 revenue booked was £0.2m; new business secured was £0.3m versus £0.1m in Q3 2025.
9M cash operating loss decreased 60% YoY to £4.0m from £9.7m; cash and cash equivalents were £1.4m at 30 September 2026.
FY 2026 revenue is expected at ~£1.8m, up 29% YoY from £1.4m in FY 2025; a further £0.1m of business was secured in early October.
Outlook and guidance
Q4 investment in growth, product and service optimisation, and new product development is expected to raise average monthly cash expenditure by £0.1m from Q3's £0.4m cash burn.
Following receipt of the anticipated £0.8m R&D tax credit, cash runway is expected to extend through Q1 2027.
FY 2027 revenue guidance is £3.0m–£4.0m, reflecting anticipated commercial momentum, pipeline expansion and benefits of 2026 operational improvements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CelLBxHealth
- Q2 revenue doubled and cost base was cut, but funding beyond Q2 2027 remains uncertain.CLBX
H1 2026 - Restructuring and key partnerships set the stage for strong revenue growth and EBITDA targets.CLBXH2 2025
- Restructuring and cost cuts drive a projected 50% revenue increase for FY 2026.CLBXQ1 2026 TU
- FY2025 revenue was £1.4M, with cost cuts and partnerships driving targeted FY26 growth.CLBXQ4 2025 TU
- Fundraise, restructuring, and partnerships drive CTC diagnostics growth and target 2028 profitability.CLBXInvestor Update
- Revenue fell to £0.8m, but cost controls and new contracts support growth and cash runway into 2026.CLBXH1 2025
- Large pharma contracts and cost controls set the stage for growth and cashflow positive trading by 2026.CLBXH1 2024
- Revenue doubled and losses narrowed as commercial momentum builds and cash runway extends.CLBXH2 2023
- Patented blood test isolates living tumor cells, enabling earlier, more precise cancer care.CLBXEmerging Growth Conference 79
CelLBxHealth
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ANGLE plc is a British medical diagnostics company focused on developing liquid biopsy solutions for cancer diagnostics. The company’s proprietary Parsortix system enables the capture and analysis of circulating tumor cells (CTCs) from patient blood samples, allowing for non-invasive cancer detection, monitoring, and personalized treatment insights. ANGLE’s technology is used in clinical research and trials, supporting advancements in oncology by providing real-time data on tumor progression and response to therapy. The company is headquartered in Guildford, United Kingdom, and its shares are listed on the London Stock Exchange and the Nasdaq.